Alpha Centric Advisors LLC Biomarin Pharmaceutical Inc Transaction History

Alpha Centric Advisors LLC

$118 Million
Q3 2024

A detailed history of Alpha Centric Advisors LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Alpha Centric Advisors LLC holds 32,500 shares of BMRN stock, worth $2.27 Million. This represents 1.93% of its overall portfolio holdings.

Number of Shares

32,500

Previous 16,500 96.97%

Holding current value

$2.27 Million

Previous $1.36 Million 68.19%

% of portfolio

1.93%

Previous 1.12%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 30, 2024	BUY	$69.02 - $93.84 $1.1 Million - $1.5 Million	16,000 Added 96.97%	32,500 $2.28 Million
Q2 2024 Jul 25, 2024	BUY	$74.43 - $92.22 $74,430 - $92,220	1,000 Added 6.45%	16,500 $1.36 Million
Q1 2024 Apr 24, 2024	BUY	$83.81 - $99.0 $125,715 - $148,500	1,500 Added 10.71%	15,500 $1.35 Million
Q4 2023 Feb 14, 2024	SELL	$76.22 - $98.51 $190,550 - $246,275	-2,500 Reduced 15.15%	14,000 $1.35 Million
Q2 2023 Aug 08, 2023	BUY	$86.68 - $100.3 $953,480 - $1.1 Million	11,000 Added 200.0%	16,500 $1.43 Million
Q1 2023 May 12, 2023	BUY	$87.74 - $117.27 $482,570 - $644,985	5,500 New	5,500 $534,000
Q3 2022 Nov 08, 2022	SELL	$82.16 - $96.94 $780,520 - $920,930	-9,500 Closed	0 $0
Q4 2021 Feb 25, 2022	BUY	$71.72 - $91.47 $107,580 - $137,205	1,500 Added 18.75%	9,500 $839,000
Q1 2021 Mar 09, 2022	BUY	$74.73 - $90.69 $37,365 - $45,345	500 Added 6.67%	8,000 $604,000
Q4 2020 Mar 11, 2022	BUY	$72.61 - $90.2 $381,202 - $473,550	5,250 Added 233.33%	7,500 $658,000
Q3 2020 Mar 11, 2022	BUY	$71.87 - $131.03 $161,707 - $294,817	2,250 New	2,250 $171,000

Others Institutions Holding BMRN

# of Institutions

630

Shares Held

184M

Call Options Held

1.63M

Put Options Held

1.2M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Centric Advisors LLC with notifications on news.

Account

Alpha Centric Advisors LLC Biomarin Pharmaceutical Inc Transaction History